Literature DB >> 31838659

A Large Cohort of RAG1/2-Deficient SCID Patients-Clinical, Immunological, and Prognostic Analysis.

Noa Greenberg-Kushnir1,2, Yu Nee Lee3,4, Amos J Simon3,4, Atar Lev3,4, Nufar Marcus5,6, Omar Abuzaitoun7, Raz Somech3,5,4, Tali Stauber3,5.   

Abstract

INTRODUCTION: Severe combined immunodeficiency (SCID) is a fatal disorder resulting from various genetic defects. In the Middle East, where consanguineous marriage is prevalent, autosomal recessive mutations in recombination-activating genes (RAG) are a leading cause of SCID. We present a large cohort of SCID patients due to RAG1 or RAG2 mutations.
METHODS: Twenty-six patients with RAG1 or RAG2 deficiency, diagnosed at Sheba Medical Center, were retrospectively investigated. Clinical presentation, immunologic phenotype, genetic analysis, treatment, and outcome were analyzed.
RESULTS: Majority of patients were referred from the Palestinian Authority. Most patients were males of Muslim Arab descent, 77% were born to consanguineous parents, and 65% had family history of immunodeficiency. Nearly all patients suffered from various infections before turning 2 months old, eight patients (31%) presented with Omenn and Omenn-like syndrome, and three patients (11%) had maternal engraftment. Notably, seven patients (27%) suffered from vaccine-derived infections, including a rare case of measles encephalitis. Nineteen patients underwent hematopoietic stem cell transplantation (HSCT) at a median age of 6 months, with a successful outcome for 72% of them. Genetic analysis revealed 11 different mutations (7 RAG2, 4 RAG1), two of them novel.
CONCLUSIONS: Consanguineous marriages account for a genetic "founder effect." SCID is a pediatric emergency that dictates immediate precautions and curative treatment with HSCT. Due to lack of newborn screening for SCID within the Palestinian population, most patients in this cohort were diagnosed upon clinical symptoms, which led to a delayed diagnosis, harmful administration of contra-indicated live vaccines, delay in HSCT, and poor outcome.

Entities:  

Keywords:  RAG1/RAG2 mutations; SCID; founder effect; live vaccines; newborn screening

Mesh:

Substances:

Year:  2019        PMID: 31838659     DOI: 10.1007/s10875-019-00717-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  3 in total

Review 1.  TREC Based Newborn Screening for Severe Combined Immunodeficiency Disease: A Systematic Review.

Authors:  Jet van der Spek; Rolf H H Groenwold; Mirjam van der Burg; Joris M van Montfrans
Journal:  J Clin Immunol       Date:  2015-04-17       Impact factor: 8.317

2.  First Year of Israeli Newborn Screening for Severe Combined Immunodeficiency-Clinical Achievements and Insights.

Authors:  Erez Rechavi; Atar Lev; Amos J Simon; Tali Stauber; Suha Daas; Talia Saraf-Levy; Arnon Broides; Amit Nahum; Nufar Marcus; Suhair Hanna; Polina Stepensky; Ori Toker; Ilan Dalal; Amos Etzioni; Shlomo Almashanu; Raz Somech
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

Review 3.  Primary Immunodeficiency Diseases in Highly Consanguineous Populations from Middle East and North Africa: Epidemiology, Diagnosis, and Care.

Authors:  Hamoud Al-Mousa; Bandar Al-Saud
Journal:  Front Immunol       Date:  2017-06-26       Impact factor: 7.561

  3 in total
  5 in total

1.  Exploring genetic defects in adults who were clinically diagnosed as severe combined immune deficiency during infancy.

Authors:  Ido Somekh; Atar Lev; Ortal Barel; Yu Nee Lee; Ayal Hendel; Amos J Simon; Raz Somech
Journal:  Immunol Res       Date:  2021-02-18       Impact factor: 2.829

Review 2.  RAG deficiencies: Recent advances in disease pathogenesis and novel therapeutic approaches.

Authors:  Marita Bosticardo; Francesca Pala; Luigi D Notarangelo
Journal:  Eur J Immunol       Date:  2021-03-22       Impact factor: 6.688

3.  Clinical, Immunological, and Molecular Variability of RAG Deficiency: A Retrospective Analysis of 22 RAG Patients.

Authors:  Cristina Cifaldi; Beatrice Rivalta; Donato Amodio; Algeri Mattia; Lucia Pacillo; Silvia Di Cesare; Maria Chiriaco; Giorgiana Madalina Ursu; Nicola Cotugno; Carmela Giancotta; Emma C Manno; Veronica Santilli; Paola Zangari; Galaverna Federica; Giuseppe Palumbo; Pietro Merli; Paolo Palma; Paolo Rossi; Gigliola Di Matteo; Franco Locatelli; Andrea Finocchi; Caterina Cancrini
Journal:  J Clin Immunol       Date:  2021-10-18       Impact factor: 8.317

Review 4.  Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma.

Authors:  E Cuperus; A Bygum; L Boeckmann; C Bodemer; M C Bolling; M Caproni; A Diociaiuti; S Emmert; J Fischer; A Gostynski; S Guez; M E van Gijn; K Hannulla-Jouppi; C Has; A Hernández-Martín; A E Martinez; J Mazereeuw-Hautier; M Medvecz; I Neri; V Sigurdsson; K Suessmuth; H Traupe; V Oji; S G M A Pasmans
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-15       Impact factor: 9.228

5.  The Clinical and Genetic Spectrum of 82 Patients With RAG Deficiency Including a c.256_257delAA Founder Variant in Slavic Countries.

Authors:  Svetlana O Sharapova; Małgorzata Skomska-Pawliszak; Yulia A Rodina; Beata Wolska-Kuśnierz; Nel Dabrowska-Leonik; Bozena Mikołuć; Olga E Pashchenko; Srdjan Pasic; Tomáš Freiberger; Tomáš Milota; Renata Formánková; Anna Szaflarska; Maciej Siedlar; Tadej Avčin; Gašper Markelj; Peter Ciznar; Krzysztof Kalwak; Sylwia Kołtan; Teresa Jackowska; Katarzyna Drabko; Alenka Gagro; Małgorzata Pac; Elissaveta Naumova; Snezhina Kandilarova; Katarzyna Babol-Pokora; Dzmitry S Varabyou; Barbara H Barendregt; Elena V Raykina; Tatiana V Varlamova; Anna V Pavlova; Hana Grombirikova; Maruša Debeljak; Irina V Mersiyanova; Anastasiia V Bondarenko; Liudmyla I Chernyshova; Larysa V Kostyuchenko; Marina N Guseva; Jelena Rascon; Audrone Muleviciene; Egle Preiksaitiene; Christoph B Geier; Alexander Leiss-Piller; Yasuhiro Yamazaki; Tomoki Kawai; Jolan E Walter; Irina V Kondratenko; Anna Šedivá; Mirjam van der Burg; Natalia B Kuzmenko; Luigi D Notarangelo; Ewa Bernatowska; Olga V Aleinikova
Journal:  Front Immunol       Date:  2020-06-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.